94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)

J Fang,B Han,G Chen,Z Yang,M Bi,C Molife,Y Zhao,L Zhang

doi:10.1016/j.annonc.2021.10.112

94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)

J Fang, B Han + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2021.10.112

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Dec 1, 2021
License type: publisher-specific-oa

Affiliation: Peking University Cancer Hospital, Shanghai Chest Hospital, Third Affiliated Hospital of Harbin Medical University, Guangdong Medical College, First Affiliated Hospital of Bengbu Medical College, Eli Lilly (United States), Sun Yat-sen University Cancer Center

#Metastatic Nonsquamous NSCLC #Therapy In Chinese Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In ORIENT-11, sint + pem + plt provided meaningful improvement in PFS and OS over pbo + pem + plt as first-line therapy in Chinese patients with locally advanced or metastatic nonsquamous NSCLC. This abstract summarized PRO results from ORIENT-11.

Full Text